Cavayas et al. recently described invasive fungal infections in patients under extra-corporeal membrane oxygenation (ECMO) of the Extracorporeal Life Support Organization registry \[[@CR1]\]. They found a 1.2% prevalence of *Candida* bloodstream infections (BSI). However, we highlighted the heterogeneity of this mixed population treated with veno-venous (VV) and veno-arterial (VA) ECMO and the scarce available data, in particular the delay from ECMO to infection \[[@CR2]\].

As no specific report is available on *Candida* BSI under VA-ECMO, we investigated the incidence and timing of this complication in our large database of 150 VA-ECMO (January 2013 to January 2017) who survived more than 24 h (Table [1](#Tab1){ref-type="table"}). Our surveillance protocol includes systematic blood culture (BC) once daily, since ECMO implantation up to 5 days after support withdrawal. Of the 2163 BC samples collected, either as routine or "on-demand" by the attending physician, 192 were positive; after exclusion of contaminants, 117 BC (61%) were related to bacterial infection in 46 patients. Only 7 (0.04%) were positive for yeasts, for a total of 5 BSI episodes in 4 patients. BSI rate was 43 cases/1.000 days of ECMO support. All yeast BSI were positive for *Candida* spp. In all cases, candidemia occurred in the third week after VA-ECMO implantation: delay between ECMO implantation and first positive BC was 17 \[16--19\] days. In one patient, candidemia occurred 4 days after ECMO withdrawal. Weaning from ECMO occurred in all 4 patients after 20 \[17--21\] days; moreover, only the patient with candidemia after ECMO withdrawal survived. Among the 46 patients with bacterial BSI, 27 died. Table 1Patients characteristicsAll patients\
(*n* = 150)Patients with *Candida* BSI\
(*n* = 4)Age (years)58 \[48--69\]50 \[40--57\]BMI (kg/m^2^)25 \[23--29\]28 \[26--29\]Long-term corticosteroid therapy7 (5)0 (0)SAPS II54 \[38--70\]41 \[35--49\]SOFA score at day 013 \[11--15\]12 \[12--12\]Arterial lactate level at day 0 (mmol/L)5 \[3--9\]6 \[3--10\]VA-ECMO for post-cardiotomy shock65 (43)2 (50)VA-ECMO for medical reason85 (57)2 (50) Refractory cardiac arrest39 (26)1 (25) Graft failure after heart transplantation14 (9)0 (0)Intra-aortic balloon pump26 (17)0 (0)KDIGO stage at day 0 052 (35)2 (50) 140 (27)0 (0) 221 (14)1 (25) 332 (22)1 (25)RRT during VA-ECMO course63 (42)3 (75)Red blood cell units at day 14 \[0--8\]9 \[5--12\]Upper gastrointestinal tract bleeding22 (14)3 (75)Enteral nutrition in the first 5 days128 (86)4 (100)Acute mesenteric ischemia during ECMO course14 (9)2 (50)Antimicrobial therapy during ECMO course134 (89)4 (100)Pneumonia during VA-ECMO support76 (51)0 (0)At least one extra-pulmonary infection during VA-ECMO support68 (45)3 (75)VA-ECMO support duration (days)7 \[5--13\]20 \[17--21\]Mechanical ventilation duration (days)14 \[6--27\]19 \[18--22\]ICU mortality84 (56)3 (75)Data are expressed as median \[interquartile 25--75\] or number (percentage), as appropriateAbbreviations: *BMI* body mass index, *BSI* bloodstream infection, *VA-ECMO* veno-arterial extra-corporeal membrane oxygenation, *SAPS II* Simplified Acute Physiology Score II, *SOFA* Sequential Organ Failure Assessment, *KDIGO* Kidney Disease: Improving Global Outcomes, *RRT* renal replacement therapy, *ICU* intensive care unit

Prevalence of invasive *Candida* disease ranges from 0 to a third of patients under ECMO \[[@CR3], [@CR4]\]. However, studies included both VV and VA-ECMO, without clear distinction between *Candida* BSI and other forms of *Candida* infections and without data on the timing of BSI occurrence. Moreover, whether BC were performed systematically or on-demand remains unknown. While it was difficult to draw conclusions with these heterogeneous populations, our results highlight that *Candida* BSI is rare and occurs late during the ECMO course. On the opposite, early septic shock under VA-ECMO is frequent and largely due to bacteria \[[@CR5]\]. Consequently, antifungal therapy should not be part of the first-line empiric antimicrobial therapy in case of septic shock occurring within the first 2 weeks of ECMO support, unless indicated for other conditions (i.e., prolonged febrile neutropenia or tertiary peritonitis). Sepsis under prolonged mechanical support should raise the possibility of invasive *Candida* infection.
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